Cardiac resynchronization therapy for enabling guideline-directed medical therapy optimization in heart failure.

ABSTRACT:

Aims

We aimed to assess whether cardiac resynchronization therapy (CRT) might serve as an enabler for guideline-directed medical therapy (GDMT) optimization.

Methods and results

Patients with heart failure with reduced ejection fraction (HFrEF) enrolled in the Swedish Heart Failure Registry between January 2009 and August 2022 were considered. Patients receiving a CRT close to the index registration were the cases, whereas controls had not received a CRT despite having an indication. Overall, 1543 (25%) HFrEF cases and 4537 (75%) controls were analysed in the intention-to-treat analysis. At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor

SUBMITTER: Tomasoni D 

PROVIDER: S-EPMC12575411 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature